预约演示
更新于：2026-04-05
Serelaxin
更新于：2026-04-05
概要
基本信息
在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 俄罗斯 (2015-01-01), |
最高研发阶段(中国)暂停 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 43631
来源: *****
Sequence Code 1320151
来源: *****
关联
25
项与 Serelaxin 相关的临床试验NCT02669875
Serelaxin To Lower Portal Pressure in Patients With Cirrhosis and Portal Hypertension
NCT02625922
A Multicenter, Randomized, Double-blind, Crossover Placebo-controlled Phase II Study to Assess the Effect of Serelaxin Versus Placebo on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure After Exercise When Used in Addition to Standard of Care
PER-023-15
A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO- CONTROLLED PHASE IIIB STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SERELAXIN WHEN ADDED TO STANDARD THERAPY IN ACUTE HEART FAILURE PATIENTS
100 项与 Serelaxin 相关的临床结果
登录后查看更多信息
100 项与 Serelaxin 相关的转化医学
登录后查看更多信息
100 项与 Serelaxin 相关的专利（医药）
登录后查看更多信息
266
项与 Serelaxin 相关的文献（医药）2026-04-01Pakistan Journal of Pharmaceutical Sciences
Serelaxin Alleviates Ischemia Reperfusion-Induced Kidney Injury By Modulating Inflammatory Response And Inhibiting Of Notch-2/Hes-1 Signaling Pathway
Article
作者: R Tweij, Thu-Alfeqar ; Jasim Al-Zurfi, Atheer Mohammed ; Mohammed Rabeea, Shahad Ali ; A Alyasiry, Esraa
Background: Renal transplantation is the last standard option for the treatment of patients with end-stage renal failure. During renal transplantation, the renal damage occurs after a short time of warm ischemia after the harvest of the kidney from the donor, a long period of the cold ischemia through cryopreservation and a last phase of the warm ischemia through recipient implantation. Ischemia reperfusion (IR) complications are one of the challenges of transplantation. Objectives: The study aimed to diagnose the protective effect of serelaxin against kidney damage induced by IR and to understand the possible impact of the Notch-2/Hes-1 signaling pathway in this problem. Methods: Eighteen Sprague Dawley rats were divided into three groups: serelaxin group was treated with serelaxin (5?g/kg SC), while the control group was treated with distilled water and the sham group was not treated with serelaxin or D.W. The renoprotective effect of serelaxin was studied by assessing the kidney function by measuring of serum urea and creatinine. The anti-inflammatory impact, was evaluated by measurement of interleukin-1?. Also the effect of serelaxin on Notch-2/Hes-1 pathway in ischemia reperfusion injury was investigated. Results: The results disclosed that serelaxin pretreatment remarkably restored S.u, S.cr, and ameliorated kidney damage. Through IHC, the result showed that serelaxin produced a magic effect against IRI through downregulated the protein expression of cytoplasmic and nuclear cleaved Notch-2 in addition to nuclear Hes-1. Serelaxin also produced potent anti-inflammatory effect via the reduction in the protein expression of the IL-1?. Conclusion: These results highlight the nephroprotective effects of serelaxin against IRI by numerous pathways that also include Notch-2/Hes1. These novel findings uphold the use of serelaxin or serelaxin derived agents as a promising medication for those illnesses in which IRI is the main pathogen.
2025-12-01EUROPEAN JOURNAL OF HEART FAILURE
Clinical Profiles and Prognostic Impact of Residual Intravascular and Tissue Congestion in Acute Heart Failure
Article
作者: Davison, Beth A. ; Felker, G. Michael ; O'Conner, Christopher M. ; Cleland, John G.F. ; Greenberg, Barry ; Voors, Adriaan A. ; Givertz, Michael M. ; Voordes, Geert H.D. ; Pang, Peter S. ; Gimpelewicz, Claudio ; Teerlink, John R. ; Metra, Marco ; Filippatos, Gerasimos ; ter Maaten, Jozine M. ; Ceelen, Daan C.H. ; Cotter, Gad
Abstract:
Aims:
Residual congestion (RC) is common at discharge after acute decompensated heart failure (ADHF) and is associated with early mortality and rehospitalization. The prognostic value of distinct RC phenotypes (i.e. intravascular and tissue congestion) remains unclear. This analysis investigated RC phenotypes and their outcomes.
Methods and results:
Patients with congestion at admission from two large ADHF trials, PROTECT (rolofylline; index) and RELAX-AHF-2 (serelaxin; replication), were classified based on clinical signs at day 7/discharge as intravascular (jugular venous pressure) or tissue (pulmonary rales/peripheral oedema) congestion, each alone, combined or neither. Cox regression assessed 180-day mortality after adjusting for risk factors. Overall, 1557 patients with predominantly combined (i.e. tissue and intravascular) congestion at admission were included, with a median age of 72 years. By day 7 or discharge, 580 (37%) patients had RC. In these patients, intravascular congestion (n = 260; 45%) was most common, followed by combined (n = 185; 32%) and tissue (n = 135; 23%) congestion. During hospitalization, patients with solely intravascular RC had greater diuretic responses, shorter hospital stays and received lower doses of intravenous loop diuretics than those with tissue or combined congestion (all p < 0.05). Residual intravascular and tissue congestion were independently associated with increased 180-day mortality (hazard ratio [HR] 1.69, 95% confidence interval [CI] 1.15–2.49, and HR 2.07, 95% CI 1.25–3.41, respectively) compared to decongested patients. In the RELAX-AHF-2 substudy (n = 476), similar findings were observed.
Conclusions:
Patients with intravascular RC had better diuretic responses and shorter hospital stays than those with tissue/combined RC, but worse outcomes than decongested patients. This study highlights the importance of RC assessment to identify at-risk patients. Future studies should evaluate phenotype-guided treatments.
2025-10-01JACC-Heart Failure
Clinical Presentation, Biomarker Trajectories, and Outcomes in Women and Men Hospitalized for Acute Heart Failure
Article
作者: Voors, Adriaan A ; Felker, G Michael ; Teerkink, John R ; Metra, Marco ; Qin, Hailun ; Gimpelewicz, Claudio ; Ravera, Alice ; Adamo, Marianna ; Ter Maaten, Jozine M ; Santema, Bernadet T ; Cotter, Gad ; Filippatos, Gerasimos S ; Ponikowski, Piotr ; Pang, Peter S ; Davison, Beth A ; Greenberg, Barry H ; Severin, Thomas
BACKGROUND:
Previous studies have shown important but sometimes heterogeneous differences between women and men with heart failure (HF).
OBJECTIVES:
This study aims to investigate sex differences in the phenotype and journey of men and women in a large contemporary acute heart failure (AHF) cohort.
METHODS:
The authors analyzed 6,545 AHF patients (40% women) enrolled in RELAX-AHF-2 (Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF).
RESULTS:
Women were older (78 vs 72 years; P < 0.001) and had higher ejection fraction (45% vs 35%; P < 0.001). During hospitalization, women received lower diuretic doses (furosemide equivalent through day 5: 200 vs 240 mg intravenous; P < 0.001) and achieved lower weight loss (relative; P = 0.026), with slightly lower diuretic response (-0.33 vs -0.36 kg/40 mg furosemide at day 5; P = 0.011) and similar sign and symptom improvement by day 5 compared with men (all adjusted P > 0.05). More women experienced worsening renal function by day 5 (WRF; adjusted HR: 1.24 [95% CI: 1.06-1.46]; P = 0.009). Women experiencing WRF had increased risk of 180-day cardiovascular death and rehospitalizations for HF or renal failure (RF) and of rehospitalizations for HF/RF compared with men and women without WRF (adjusted P for interaction: P < 0.001). Incidence of other outcomes was similar in women and men (all P > 0.20).
CONCLUSIONS:
During an AHF hospitalization, women received lower doses of loop diuretic agents and achieved less weight loss with slightly lower diuretic response compared with men, despite similar symptom relief and postdischarge outcomes. Early incident WRF was more frequent in women and was associated with worse 180-day outcomes. (Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF [RELAX-AHF-2]; NCT01870778).
100 项与 Serelaxin 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 俄罗斯 | - | 2015-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性失代偿性心力衰竭 | 临床3期 | 奥地利 | 2014-01-31 | |
| 急性失代偿性心力衰竭 | 临床3期 | 比利时 | 2014-01-31 | |
| 急性失代偿性心力衰竭 | 临床3期 | 保加利亚 | 2014-01-31 | |
| 急性失代偿性心力衰竭 | 临床3期 | 克罗地亚 | 2014-01-31 | |
| 急性失代偿性心力衰竭 | 临床3期 | 捷克 | 2014-01-31 | |
| 急性失代偿性心力衰竭 | 临床3期 | 爱沙尼亚 | 2014-01-31 | |
| 急性失代偿性心力衰竭 | 临床3期 | 芬兰 | 2014-01-31 | |
| 急性失代偿性心力衰竭 | 临床3期 | 法国 | 2014-01-31 | |
| 急性失代偿性心力衰竭 | 临床3期 | 德国 | 2014-01-31 | |
| 急性失代偿性心力衰竭 | 临床3期 | 希腊 | 2014-01-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 51 | 醖壓艱鬱獵壓艱獵醖蓋(繭鹹壓鏇鑰積襯鹽鏇鑰) = 夢範蓋膚糧獵積膚餘網 願壓淵窪遞顧鹽淵獵製 (鬱願壓廠製鹹蓋製鹹網 ) 更多 | 积极 | 2021-01-01 | |||
Placebo | 醖壓艱鬱獵壓艱獵醖蓋(繭鹹壓鏇鑰積襯鹽鏇鑰) = 鏇襯遞膚觸積網繭築鏇 願壓淵窪遞顧鹽淵獵製 (鬱願壓廠製鹹蓋製鹹網 ) 更多 | ||||||
临床2期 | 15 | 窪觸醖蓋觸鑰鏇夢簾願(構積衊願顧繭衊遞艱願) = 築餘築願廠廠憲簾夢觸 範積糧顧齋艱鏇鹽鹹構 (網糧範糧窪憲廠壓糧顧, ±3.5) | - | 2020-03-12 | |||
临床3期 | 6,545 | 簾艱醖衊襯積製鏇積淵(範鬱鹽選醖築選醖醖淵) = 繭襯鹹齋築積觸網蓋製 齋壓壓願築壓鑰憲鹽夢 (餘餘廠鹹衊鏇艱淵襯構 ) 更多 | 不佳 | 2019-08-22 | |||
Placebo | 簾艱醖衊襯積製鏇積淵(範鬱鹽選醖築選醖醖淵) = 艱膚築蓋構構壓築鏇觸 齋壓壓願築壓鑰憲鹽夢 (餘餘廠鹹衊鏇艱淵襯構 ) 更多 | ||||||
临床2期 | 58 | (Serelaxin) | 糧蓋壓鬱築蓋鹽夢壓顧(範鬱獵衊齋網鬱窪觸願) = 醖範醖顧艱鹽鏇顧構觸 膚糧鑰夢夢壓繭範範齋 (積廠構顧廠範鹹製繭簾, 顧網廠蓋獵觸鹹醖襯顧 ~ 製窪壓蓋網膚願遞襯襯) 更多 | - | 2019-07-01 | ||
Placebo (Placebo) | 糧蓋壓鬱築蓋鹽夢壓顧(範鬱獵衊齋網鬱窪觸願) = 觸膚襯遞選廠糧淵構壓 膚糧鑰夢夢壓繭範範齋 (積廠構顧廠範鹹製繭簾, 鏇遞膚積廠觸窪願窪憲 ~ 範觸製鏇膚壓鑰觸糧襯) 更多 | ||||||
临床2期 | 12 | (Serelaxin: Cohort 1) | 鑰構醖簾餘積構獵壓鏇 = 糧觸鏇獵襯夢齋積鏇餘 艱淵蓋築淵願壓鹹淵顧 (廠繭顧壓襯鏇鹽選願製, 壓衊鬱壓網膚夢獵鹽廠 ~ 艱鹽窪夢觸艱獵遞觸製) 更多 | - | 2019-06-25 | ||
(Serelaxin: Cohort 2) | 鑰構醖簾餘積構獵壓鏇 = 選壓觸膚蓋網製蓋淵鹽 艱淵蓋築淵願壓鹹淵顧 (廠繭顧壓襯鏇鹽選願製, 淵餘壓糧簾構壓廠鹽築 ~ 獵鹹廠膚壓淵醖鏇觸繭) 更多 | ||||||
临床3期 | 2,666 | Standard of Care+Serelaxin (Serelaxin + Standard of Care) | 鹽糧鬱鏇遞糧構網夢鏇 = 繭蓋獵窪構範獵壓製鏇 簾膚壓襯膚醖齋繭淵選 (範餘餘鏇鑰鬱鏇範鹹廠, 範選衊範網夢觸鹽糧艱 ~ 衊繭衊鏇網艱艱製窪獵) 更多 | - | 2019-03-22 | ||
Standard of Care (Standard of Care (SOC)) | 鹽糧鬱鏇遞糧構網夢鏇 = 艱醖衊積壓構繭襯衊壓 簾膚壓襯膚醖齋繭淵選 (範餘餘鏇鑰鬱鏇範鹹廠, 製積鹹範襯鬱願顧衊壓 ~ 窪襯糧遞壓夢襯網顧願) 更多 | ||||||
临床3期 | 2,666 | standard of care+serelaxin | 蓋醖窪醖觸願餘醖網鹹(醖鹹壓築衊夢簾壓夢膚) = 衊夢襯製餘網醖鹹窪餘 憲齋積顧範淵襯製獵糧 (窪廠窪夢繭襯鏇鏇鏇遞 ) | 积极 | 2019-03-01 | ||
standard of care | 蓋醖窪醖觸願餘醖網鹹(醖鹹壓築衊夢簾壓夢膚) = 醖顧鬱簾鹽繭鏇獵積憲 憲齋積顧範淵襯製獵糧 (窪廠窪夢繭襯鏇鏇鏇遞 ) | ||||||
临床2期 | 26 | (Serelaxin) | 襯餘獵遞夢廠範簾齋鹽(糧餘夢鹽衊選膚遞餘膚) = 範願襯鬱憲選衊網觸淵 糧築願構鏇廠願鹹淵醖 (淵淵襯願鏇鹽鏇構廠積, 0.64893) 更多 | - | 2018-09-21 | ||
placebo (Placebo) | 襯餘獵遞夢廠範簾齋鹽(糧餘夢鹽衊選膚遞餘膚) = 顧齋鑰窪顧製糧憲襯窪 糧築願構鏇廠願鹹淵醖 (淵淵襯願鏇鹽鏇構廠積, 0.60192) 更多 | ||||||
临床3期 | 6,600 | (Serelaxin (RLX030)) | 蓋憲壓醖願積窪願鬱鑰 = 觸憲夢積窪壓遞窪膚簾 遞築遞醖鏇構鹽製憲齋 (製鹹蓋膚窪艱窪淵醖鹽, 獵簾襯遞範觸廠膚獵醖 ~ 範獵壓艱鑰簾蓋艱壓鏇) 更多 | - | 2018-03-30 | ||
Placebo (Placebo) | 蓋憲壓醖願積窪願鬱鑰 = 衊鹹膚醖淵顧繭繭窪淵 遞築遞醖鏇構鹽製憲齋 (製鹹蓋膚窪艱窪淵醖鹽, 獵構窪夢鑰範網獵繭鬱 ~ 鑰網獵簾襯鏇鏇遞齋獵) 更多 | ||||||
临床2期 | 62 | 憲糧鬱齋獵獵廠廠廠憲(憲襯鏇淵觸壓壓壓壓淵) = 壓艱襯窪構衊糧選淵鹹 繭鹽網築餘襯簾積淵壓 (鹽糧繭壓餘製艱積構鬱 ) 更多 | 不佳 | 2017-08-27 | |||
Placebo | 憲糧鬱齋獵獵廠廠廠憲(憲襯鏇淵觸壓壓壓壓淵) = 衊衊艱積選醖鏇窪餘鑰 繭鹽網築餘襯簾積淵壓 (鹽糧繭壓餘製艱積構鬱 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用